#ASH17: Roche unveils stellar PhII DLBCL data for one of its top hematology drugs in the pipeline
One of Genentech’s top experimental hematology drugs has delivered outstanding results in a mid-stage study for aggressive cases of diffuse large B-cell lymphoma, a field that has been overshadowed by the two approved CAR-Ts in the field.
Newly rewarded a breakthrough therapy designation from the FDA — and a similar status from the EMA — investigators say they tracked a complete response rate of 40% in the Phase II trial. The drug — polatuzumab vedotin — was added to bendamustine and Rituxan (BR), a combo that provided a 15% CR rate in the control arm that was clearly overshadowed by the triplet.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
